Tirzepatide
Also known as: Mounjaro, Zepbound, LY3298176
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By activating both incretin pathways simultaneously, it achieves greater improvements in glycemic control and weight loss than single-receptor agonists. The SURMOUNT clinical trial program demonstrated average weight loss of 20-26% of body weight at the highest dose over 72 weeks, surpassing results seen with GLP-1 agonists alone. It is administered as a once-weekly subcutaneous injection with dose titration over several weeks to minimize gastrointestinal side effects.
Extensive clinical evidence
Well-tolerated with minimal side effects
How It Works
Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both receptors for enhanced insulin secretion, reduced appetite, and improved metabolic function.
Key Benefits
- Industry-leading weight loss efficacy
- Superior glycemic control for type 2 diabetes
- Reduced appetite through dual-incretin action
- Improved insulin sensitivity
- Beneficial effects on blood pressure and lipid profiles
- Potential reduction in cardiovascular events
- Decreased systemic inflammation
- Decreased risk of kidney disease and dementia
Who May Benefit
- Individuals seeking maximum weight loss potential
- People with type 2 diabetes needing aggressive control
- Patients who plateaued on Semaglutide
- Those seeking the most potent weight management peptide
Dosage & Administration
Expected Timeline
Appetite suppression in the first week. Significant weight loss by 12 weeks. Up to 22.5% average loss at 72 weeks.
Safety Information
Possible Side Effects
Contraindications
Dr. Taylor's 2 Cents
“Tirzepatide is the most exciting development in metabolic medicine and my go to for metabolic protocols (for now). The dual GIP/GLP-1 mechanism produces weight loss results we've never seen before — 20%+ in clinical trials. I'm seeing similar results in practice. It's particularly effective for patients with insulin resistance and metabolic syndrome. The key is slow dose titration to minimize GI side effects. This is prescription-only and requires close physician monitoring.”
Discuss with Dr. Taylor →Frequently Asked Questions
What makes it different from Semaglutide?
How much weight loss is possible?
Is Tirzepatide FDA approved?
What are the side effects?
How is it dosed?
Can I switch from Semaglutide?
Published Research
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al. · New England Journal of Medicine (2022)
Key Finding: Tirzepatide produced mean weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo at 72 weeks in 2,539 adults with obesity.
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)
Rosenstock J, Wysham C, Frías JP, et al. · The Lancet (2021)
Key Finding: Tirzepatide reduced HbA1c by up to 2.07% and body weight by up to 9.5 kg; up to 52% of participants achieved HbA1c below 5.7%, a level seen in people without diabetes.
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Garvey WT, Frías JP, Jastreboff AM, et al. · The Lancet (2023)
Key Finding: Tirzepatide achieved mean weight reductions of 13.4% (10 mg) and 15.7% (15 mg) versus 3.3% with placebo, with significant improvements in blood pressure, triglycerides, and HDL cholesterol.
Protocols Featuring Tirzepatide
Related Peptides
Related Reading
Want personalized guidance?
Consult with Dr. Patrick Taylor for a comprehensive evaluation and personalized protocol.
Book a ConsultationMedical Disclaimer: This information is for educational purposes only and is not medical advice. Consult a healthcare provider before starting any peptide protocol.